Jasper Therapeutics, Inc.

Develops mast cell-depleting antibody therapies for chronic diseases and stem cell transplants.

JSPR | US

Overview

Corporate Details

ISIN(s):: US4718712023 (+3 more)
LEI:
Country:: United States of America
Address:: 2200 BRIDGE PKWY SUITE #102, 94065 REDWOOD CITY
Website:: https://jaspertx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for mast cell-driven diseases and as a conditioning agent for hematopoietic stem cell transplantation. The company's lead product candidate is briquilimab, a targeted anti-KIT (CD117) monoclonal antibody designed to deplete mast cells. Jasper is evaluating briquilimab in clinical studies for the treatment of chronic immunological and inflammatory diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. The company's mission is to develop safer and more effective therapies for patients with serious chronic diseases by harnessing the power of mast cell depletion.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Jasper Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Jasper Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Jasper Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Lyra Therapeutics, Inc. Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).	United States of America	LYRA
Lytix Biopharma AS Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.	Norway	LYTIX
MaaT Pharma Developing gut microbiome therapies to improve survival for cancer patients.	France	MAAT
Mabion S.A. Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.	Poland	MAB
MACROGENICS INC Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.	United States of America	MGNX
MADRIGAL PHARMACEUTICALS, INC. Develops and delivers the first FDA-approved treatment for the liver disease MASH.	United States of America	MDGL
Magle Chemoswed Holding AB A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.	Sweden	MAGLE
Mainz BioMed N.V. Develops at-home diagnostic tests for the early detection of life-threatening cancers.	Germany	MYNZ
MAINZ BIOMED N.V. Develops molecular genetic diagnostic tests for early colorectal cancer detection in the US & Europe.	United States of America	MYNZ
MANNKIND CORP Develops inhaled therapies for endocrine, orphan lung, and cardiometabolic diseases.	United States of America	MNKD